GentiBio
Hatem Heikal is the Vice President of Finance at GentiBio. Before joining the company, Hatem led strategic finance at several high-growth technology companies, where he was responsible for raising over $700M in funding, led an IPO process, and executed multiple M&A opportunities. Hatem’s career began in venture capital and private equity investing, supporting over $3B in investments across Healthcare, Financial Services, and Education. Hatem has an MBA from The Wharton School at the University of Pennsylvania.
This person is not in any teams
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.